Kurnellas et al. found that plasma PGRN and cerebrospinal fluid (CSF) PGRN were increased by using latozinemab in the first-in-human phase 1 clinical trial, which were beneficial for the treatment of GRN mutation causing frontotemporal dementia (FTD-GRN) and other neurodegenerative diseases [71]. This evidence concerns the gene GRN and neurodegenerative disease.